Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 02:00 ET | Source: Avacta Group PLC

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026

Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable...
May 19, 2026 02:14 ET | Source: Avacta Group PLC

Unaudited Preliminary Results for the Year Ended December 31, 2025

LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a...
May 06, 2026 02:00 ET | Source: Avacta Group PLC

Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026

LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a...
April 21, 2026 12:00 ET | Source: Avacta Group PLC

Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform

Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with low FAP expression and more favorable kinetic profile compared to the marketed antibody-drug...
April 14, 2026 07:26 ET | Source: Avacta Group PLC

Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders

LONDON and PHILADELPHIA, April 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a...
March 31, 2026 02:31 ET | Source: Avacta Group PLC

Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate

Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this year LONDON and PHILADELPHIA, March 31,...
March 17, 2026 03:00 ET | Source: Avacta Group PLC

Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference

LONDON and PHILADELPHIA, March 17, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a...
February 24, 2026 02:00 ET | Source: Avacta Group PLC

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® Clinical trial with AVA6103 is expected to be initiated...
February 09, 2026 02:00 ET | Source: Avacta Group PLC

Avacta appoints Francis Wilson as Chief Scientific Officer

LONDON and PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a...
February 03, 2026 07:00 ET | Source: AVACTA GROUP PLC

Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program

LONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a...